Aug. 24, 2011
, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that
Daniel P. Gold
, Ph.D., President and Chief Executive Officer, will present an update on
and its lead oncology programs at the Southern California Investor Conference on
Monday, August 29, 2011
11:30 a.m. PDT
from the Island Hotel in
Newport Beach, Calif.
A live webcast of the presentation can be accessed at
. A replay will be available approximately one hour after the presentation and archived for 60 days.
About Marshall Edwards
, Inc. (Nasdaq: MSHL) is a
-based oncology company focused on the clinical development of novel anti-cancer therapeutics. The Company's lead programs focus on two families of small molecules that result in the inhibition of tumor cell metabolism. The first and most advanced is a NADH oxidase inhibitor program that includes lead candidate ME-143. The second is a mitochondrial inhibitor program that includes lead candidate ME-344. The Company expects to initiate a Phase I clinical trial of intravenous ME-143 by
and submit an Investigational New Drug application for ME-344 by the first quarter of 2012. For more information, please visit